skip to primary navigationskip to content

Cambridge Infectious Diseases

An Interdisciplinary Research Centre at the University of Cambridge

Studying at Cambridge

 

Cambridge and India

Infectious Diseases Research in India

For a global university such as Cambridge, working together with international research partners maximises the chance of innovative ideas being transformed into practical applications that benefit communities around the world. This is crucial to the University’s mission of meeting the challenges facing society this century. India and Cambridge are becoming major partners in world-changing research, based on the firm foundations of hundreds of individual academic collaborations and pioneering research projects from  infectious diseases to fuel cells, from crop science to sustainability.

Cambridge-Chennai Centre Partnership on Antimicrobial Resistant Tuberculosis

Since 2010, the University has developed a close working relationship with the Government of India Departments of Science and Technology (DST) and Biotechnology (DBT) in India.

In 2014, discussions focussed on anti-microbial resistance (AMR). Four senior Cambridge academics joined the Vice-Chancellor and Pro-Vice-Chancellor at a UK-India round table on AMR in Bangalore, organised by the British Deputy High Commission. Following discussions with DST/DBT and the Indian Minister of Science & Technology, researchers from the Infectious Diseases Strategic Research Initiative submitted a bid with the National Institute for Research in Tuberculosis (Chennai) in response to a joint MRC-DBT Centre Partnership call in AMR. In 2015, it was announced that the Cambridge–Chennai bid had been successful, winning funding for a joint centre in AMR tuberculosis research.

A multidisciplinary team of international researchers, led by Professor Sharon Peacock (CID) and Dr Soumya Swaminathan, and including Professors Lalita Ramakrishnan (CID), Ken Smith (CID), Tom Blundell (CID) and Andres Floto (CID), will focus on developing new diagnostic tools and treatments to address the sharp rise in cases of multidrug-resistant tuberculosis.